Contact
 

FHI to Initiate Orderly Closure of FEM-PrEP

Following a scheduled interim review of data from the FEM-PrEP study of oral pre-exposure prophylaxis (PrEP) using daily TDF/FTC (brand-name Truvada), the Independent Data Monitoring Committee (IDMC) advised that the FEM-PrEP study will be highly unlikely to be able to demonstrate the effectiveness of Truvada [emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF)] in preventing HIV infection in the study population, even if it continued to its originally planned conclusion. Family Health International (FHI) subsequently concurred and has therefore decided to initiate an orderly closure of the study over the next few months. The final analyses have not yet been conducted. At this time, it cannot be determined whether or not Truvada works to prevent HIV infection in women.  The full statement is available below.

Global HIV Vaccine Enterprise, 64 Beaver Street, # 352, New York, NY 10004 | +1 212-461-3692 or toll free at +1-866-966-4483
All Content ©2005 - 2013 Global HIV Vaccine Enterprise   |   Terms of Use   |   Privacy Policy   |   Log In / My Account




Warning: INSERT command denied to user 'ghvedrupal'@'173.201.196.63' for table 'watchdog' query: INSERT INTO watchdog (uid, type, message, variables, severity, link, location, referer, hostname, timestamp) VALUES (0, 'php', '%message in %file on line %line.', 'a:4:{s:6:\"%error\";s:12:\"user warning\";s:8:\"%message\";s:384:\"INSERT command denied to user 'ghvedrupal'@'173.201.196.63' for table 'accesslog'\nquery: INSERT INTO accesslog (title, path, url, hostname, uid, sid, timer, timestamp) values('FHI to Initiate Orderly Closure of FEM-PrEP', 'node/564', '', '54.166.228.35', 0, 'gfffl37p5nlvjpl2d2qmg00ta0', 208, 1531744911)\";s:5:\"%file\";s:66:\"/home/content/79/9887379/html/modules/statistics/statistics.module\";s:5:\"%line\";i:63;}' in /home/content/79/9887379/html/includes/database.mysqli.inc on line 134